Latest Insulin Detemir Stories

RIDGEFIELD, Conn. and INDIANAPOLIS, Aug. 17, 2012 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for Tradjenta® (linagliptin) tablets for use as add-on therapy to insulin. TRADJENTA is a prescription medication used along with diet and exercise to lower blood sugar in adults with type 2 diabetes, and can be used as...

Beth Israel Deaconess Medical Center study analyzes hemoglobin A1C levels in blacks, whites Healthcare providers should take into account differences among racial groups when using hemoglobin A1C levels to diagnose and monitor diabetes, new research from Beth Israel Deaconess Medical Center suggests. In a study published Aug. 7 in the Annals of Internal Medicine, researchers analyzed National Health and Nutrition Survey data from 2005 to 2008 to examine the association between...

PHILADELPHIA, June 12, 2012 /PRNewswire/ -- One in four people with type 2 diabetes missed or did not dose their long-acting (basal) insulin correctly in the previous 30 days, according to a new global survey funded by Novo Nordisk. The GAPP2(TM) (Global Attitudes of Patients and Physicians) survey also found that more than a third experienced a self-treated low blood sugar event called hypoglycemia. The data was presented at the late-breaking poster session of the 72nd Scientific...

RIDGEFIELD, Conn. and INDIANAPOLIS, June 9, 2012 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company (NYSE: LLY) presented results from two randomized phase 3 clinical trials and a post-hoc analysis for linagliptin at the American Diabetes Association's (ADA's) 72nd Scientific Sessions®. The new studies provide additional data evaluating the efficacy and safety of linagliptin (alone or in combination with other diabetes therapies) in adults with...

PRINCETON, N.J., May 22, 2012 /PRNewswire/ -- Novo Nordisk, a world leader in diabetes care, announced today that the U.S. Food and Drug Administration (FDA) has approved Levemir(®) (insulin detemir [rDNA origin] injection) for use in children ages two to five years with type 1 diabetes. With the expansion of its pediatric indication, Levemir(®) is now available for type 1 diabetes patients from age two through adulthood and adult patients with type 2 diabetes. To view the...

GREENVILLE, S.C., May 22, 2012 /PRNewswire/ -- Glytec, LLC, headquartered in Greenville, SC, announced today that its Glucommander(TM) 2.0 Enterprise software has been cleared by the FDA for pediatric use, ages 2 - 17. Glytec's Glucommander was the first insulin dosing software to be cleared for adult (ages 18+) intravenous use; it is the only company to achieve specific clearance for subcutaneous use, and now it is the only company cleared to offer this technology to hospitals caring...

PRINCETON, N.J., April 9, 2012 /PRNewswire/ -- Novo Nordisk received approval from the U.S. Food and Drug Administration (FDA) to update the product label for Victoza(®) (liraglutide [rDNA origin] injection) to include data showing superior blood sugar control when compared to Januvia(®) (sitagliptin). Victoza(®) also provided greater weight reduction. Both products were taken in combination with metformin in adults with type 2 diabetes. To view the multimedia assets...

PRINCETON, N.J., April 2, 2012 /PRNewswire/ -- Novo Nordisk, a world leader in diabetes care, announced today that the U.S. Food and Drug Administration (FDA) has approved Levemir(®) (insulin detemir [rDNA origin] injection) for a pregnancy Category B classification, indicating that Levemir(®), when used in pregnant women with diabetes, did not increase the risk of harm to the unborn baby. To view the multimedia assets associated with this release, please click:...

PRINCETON, N.J. and INDIANAPOLIS, Ind., Nov. 15, 2011 /PRNewswire/ -- Novo Nordisk, a world leader in diabetes care, and Chip Ganassi Racing Teams, Inc. announced today that the two organizations have entered into a multi-year extension of their partnership. Novo Nordisk will remain the primary sponsor of the No. 83 Novo Nordisk Chip Ganassi Racing entry, driven by Charlie Kimball in the IZOD IndyCar Series. To view the multimedia assets associated with this release, please click:...

PRINCETON, N.J., Nov. 2, 2011 /PRNewswire/ -- Novo Nordisk, a world leader in diabetes care, announced today that it has donated $50,000 to the Diabetes Hands Foundation (DHF), a non-profit organization that raises diabetes awareness and connects people touched by the condition. The donation recognizes the success of the Drive the Switch program, which has motivated more than 10,000 people to pledge to talk to loved ones and their doctor about options for insulin delivery, like the...